Volume 17, Number 12—December 2011
Research
Candidate Cell Substrates, Vaccine Production, and Transmissible Spongiform Encephalopathies
Table 1
Cell cultures exposed to transmissible spongiform encephalopathy agents and propagated for 30 passages*
Variable | sCJD | vCJD | BSE | 22L-scrapie |
---|---|---|---|---|
Actual or candidate cell lines for vaccine production | ||||
CHO-K1 | Y | Y | Y | |
Vero C1008 | Y | Y | Y | |
WI-38 | Y | Y | Y | |
MDCK | Y | Y | Y | |
HEK-293 | Y | Y | Y | |
Other cells resistant to TSE infection | ||||
MBDK | Y | |||
EBTR | Y | |||
BT | Y | |||
BCE C/D-1b | Y | |||
BL3.1 | Y | |||
R9ab | Y | Y | Y | |
Cells infectable with 22L scrapie | ||||
Mo3F4-3T3 | Y | |||
L929 | Y |
*sCJD, sporadic Creutzfeldt-Jakob disease; vCJD, variant Creutzfeldt-Jakob disease; BSE, bovine spongiform encephalopathy; CHO-KI, Chinese hamster ovary; Vero C1008, African green monkey kidney; WI-38, human lung diploid fibroblasts; MDCK, dog kidney; HEK-293, human embryonic kidney; MBDK, bovine kidney; EBTR, bovine trachea; BT, bovine turbinate; BCE C/D-1b, bovine cornea; BL3.1, bovine B lymphocytes; R9ab, rabbit fibroblasts; Mo3F4-3T3, mouse embryo fibroblasts; L929, mouse embryo fibroblasts; Y, experiment was completed.